✦ LIBER ✦

Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin

✍ Scribed by M. G. Scott; A. H. Deering; M. T. McMahon; D. W. G. Harron; R. G. Shanks

Publisher: Springer
Year: 1989
Tongue: English
Weight: 708 KB
Volume: 37
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00609425

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single dose pharmacokinetics and bioavai

Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method

✍ U. Meresaar; M. -I. Nilsson; J. Holmstrand; E. Änggård 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 548 KB

Haemodynamic effects and pharmacokinetic

Haemodynamic effects and pharmacokinetics of a new selective beta1-adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man

✍ O. Rönn; Christina Graffner; G. Johnsson; L. Jordö; P. Lundborg; J. Wikstrand 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 525 KB

Pharmacokinetics and haemodynamic effect

Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease

✍ S. Krähenbühl; P. Grass; A. Surve; K. Kutz; J. Reichen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 637 KB

Pharmacokinetic, bioavailability and pha

Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man

✍ L. M. Fuccella; G. Corvi; E. Moro; E. Pogliani; V. Tamassia; G. Tosolini 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 439 KB

A Phase I and pharmacokinetic study of h

A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

✍ Edward F. McClay; Mary-Eileen T. McClay; Jeffery A. Jones; Paul J. Winski; Rando 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for r

A novel three-dose regimen of daclizumab

A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study

✍ W. Kenneth Washburn; Lewis W. Teperman; Thomas G. Heffron; David D. Douglas; Ste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB

This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3-dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 of Hep C 3 Liver Study), daclizumab (2, 2